These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8232238)

  • 1. Role of threonine 342 in helix 7 of the 5-hydroxytryptamine type 1D receptor in ligand binding: an indirect mechanism for receptor selectivity.
    Smolyar A; Osman R
    Mol Pharmacol; 1993 Oct; 44(4):882-5. PubMed ID: 8232238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
    Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
    Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine.
    Glennon RA; Dukat M; Westkaemper RB; Ismaiel AM; Izzarelli DG; Parker EM
    Mol Pharmacol; 1996 Jan; 49(1):198-206. PubMed ID: 8569707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
    Pauwels PJ; Gouble A; Wurch T
    Biochem J; 1999 Oct; 343 Pt 2(Pt 2):435-42. PubMed ID: 10510311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
    Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
    Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconstitution of the human 5-HT(1D) receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations.
    Brys R; Josson K; Castelli MP; Jurzak M; Lijnen P; Gommeren W; Leysen JE
    Mol Pharmacol; 2000 Jun; 57(6):1132-41. PubMed ID: 10825383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.
    Glennon RA; Hong SS; Bondarev M; Law H; Dukat M; Rakhi S; Power P; Fan E; Kinneau D; Kamboj R; Teitler M; Herrick-Davis K; Smith C
    J Med Chem; 1996 Jan; 39(1):314-22. PubMed ID: 8568822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor.
    Brüss M; Kiel S; Bönisch H; Kostanian A; Göthert M
    Neurochem Int; 2005 Aug; 47(3):196-203. PubMed ID: 15896881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.
    Zhao MM; Hwa J; Perez DM
    Mol Pharmacol; 1996 Nov; 50(5):1118-26. PubMed ID: 8913343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model structures of the N-methyl-D-aspartate receptor subunit NR1 explain the molecular recognition of agonist and antagonist ligands.
    Moretti L; Pentikäinen OT; Settimo L; Johnson MS
    J Struct Biol; 2004 Mar; 145(3):205-15. PubMed ID: 14960371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.
    Cohen ML; Schenck K
    J Pharmacol Exp Ther; 1999 Sep; 290(3):935-9. PubMed ID: 10454462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists.
    Halazy S; Perez M; Fourrier C; Pallard I; Pauwels PJ; Palmier C; John GW; Valentin JP; Bonnafous R; Martinez J
    J Med Chem; 1996 Dec; 39(25):4920-7. PubMed ID: 8960551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
    Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
    J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutagenesis analysis of the serotonin 5-HT2C receptor and a Caenorhabditis elegans 5-HT2 homologue: conserved residues of helix 4 and helix 7 contribute to agonist-dependent activation of 5-HT2 receptors.
    Xie J; Dernovici S; Ribeiro P
    J Neurochem; 2005 Jan; 92(2):375-87. PubMed ID: 15663485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
    Choi SK; Green D; Ho A; Klein U; Marquess D; Taylor R; Turner SD
    J Med Chem; 2008 Jun; 51(12):3609-16. PubMed ID: 18507369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor.
    Chanda PK; Minchin MC; Davis AR; Greenberg L; Reilly Y; McGregor WH; Bhat R; Lubeck MD; Mizutani S; Hung PP
    Mol Pharmacol; 1993 Apr; 43(4):516-20. PubMed ID: 8474430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor regulatory properties evident in the molecular similarity of serotonin receptor ligands and purine nucleotides.
    Williams WR; Pugh WJ; Nicholls PJ
    J Pharm Pharmacol; 2004 Dec; 56(12):1563-72. PubMed ID: 15563764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
    Massot O; Rousselle JC; Fillion MP; Grimaldi B; Cloëz-Tayarani I; Fugelli A; Prudhomme N; Seguin L; Rousseau B; Plantefol M; Hen R; Fillion G
    Mol Pharmacol; 1996 Oct; 50(4):752-62. PubMed ID: 8863819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists.
    López-Rodríguez ML; Benhamú B; de la Fuente T; Sanz A; Pardo L; Campillo M
    J Med Chem; 2005 Jun; 48(13):4216-9. PubMed ID: 15974573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
    Bouchelet I; Cohen Z; Case B; Séguéla P; Hamel E
    Mol Pharmacol; 1996 Aug; 50(2):219-23. PubMed ID: 8700126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.